智通财经1月8日讯（记者 何凡）今日国内第七款注射用 A 型肉毒毒素产品获批上市，该A型肉毒毒素 100U产品由爱美客（300896.SZ）从韩国Huons BP引入。随着越来越多的玩家进入肉毒毒素赛道，爱美 客能否依靠上述产品缓解业绩下滑态势值得持续关注。 爱美客方面表示，本次注射用 A 型肉毒毒素产品药品注册证的获取是公司战略布局的关键里程碑，该 产品通过与现有产品的组合，能为客户提供更全面的综合解决方案，有利于增强公司的核心竞争力。 面对每天上千份上市公司公告该看哪些？重大事项公告动辄几十页几百页重点是啥？公告里 一堆专业术语不知道算利好还是利空？请看智通财经公司新闻部《速读公告》栏目，我们派 驻全国的记者们将于公告当晚为您带来准确、快速、专业的解读。 今日晚间，爱美客公告称，公司在中国（包括澳门和香港）独家经销韩国Huons BP生产的注射用A型肉 毒毒素产品获得国家药监局核准签发的《药品注册证书》。 2022年5月20日，爱美客与Huons BP签订《经销协议》，公司以研发注册方式引进 Huons BP 生产的注 射用 A 型肉毒毒素产品，并在约定经销区域（指中国，包括澳门和香港）内作为 Huons ...

爱美客（300896）(300896.SZ)公告，公司在中国独家经销韩国Huons BP生产的注射用A型肉毒毒素产品 获得国家药品监督管理局核准签发的《药品注册证书》。 ...

（文章来源：证券日报） 证券日报网讯 1月8日，爱美客发布公告称，2026年1月8日，公司在中国（含港澳）独家经销韩国 HuonsBioPharmaCo.，Ltd.生产的注射用A型肉毒毒素获国家药监局核准签发药品注册证书，规格100U/ 瓶，批准文号国药准字SJ20260001，有效期至2031年1月4日。 ...

根据公告，2022年5月20日，爱美客与Huons BP签订《经销协议》，以研发注册方式引进Huons BP生产 的注射用A型肉毒毒素产品，并在约定经销区域（中国）内作为Huons BP指定的唯一且排他的进口商、 经销商。 北京商报讯（记者 王寅浩 宋雨盈）1月8日，爱美客发布公告称，公司在中国独家经销韩国Huons BioPharma Co., Ltd.（以下简称"Huons BP"）生产的注射用A型肉毒毒素产品获得国家药品监督管理局核 准签发的《药品注册证书》。 ...

Group 1 - The core viewpoint of the article is that Aimeike (300896.SZ) has received approval from the National Medical Products Administration for the drug registration certificate of its exclusive distribution of injectable type A botulinum toxin products produced by Huons BioPharma Co., Ltd. in China, including Macau and Hong Kong [1] - The acquisition of the drug registration certificate for the injectable type A botulinum toxin product is a key milestone in the company's strategic layout [1] - This product, combined with existing offerings, will provide customers with a more comprehensive solution, enhancing the company's core competitiveness [1]

Group 1 - Runjian Co., Ltd. signed a strategic cooperation framework agreement with JD Technology to collaborate in AI applications, intelligent computing cloud expansion, and AIDC cooperation [1] - The partnership aims to commercialize AI technology in various sectors including smart agriculture, intelligent parks, digital cultural tourism, and smart retail [1] - Both companies will enhance the "Runjian Cloud" and leverage JD's extensive market channels for business expansion [1] Group 2 - Vanke A announced that Yu Liang will retire due to age, effective January 8, 2026, and will no longer hold any position in the company [2] - The resignation will not affect the board's operation or the company's daily business [2] Group 3 - Zhong Wuyun signed a contract exceeding 100 million yuan for a drone system, which is over 50% of the company's audited revenue from the last fiscal year [3] - The contract is expected to positively impact the company's operating performance for the contract execution year [3] Group 4 - Changhong Technology's subsidiary secured over half of a major domestic wafer factory's procurement share for semiconductor consumables, amounting to over 10 million yuan [4] - This order is expected to enhance the company's market expansion in semiconductor consumables and strengthen its competitive advantage [4] Group 5 - Huibo Pu is planning to transfer 25%-30% of its shares, which may lead to a change in the controlling shareholder [5] - The stock will be suspended from trading starting January 9, 2026, for up to two trading days [5] Group 6 - Tiansheng New Materials announced that its largest shareholder is planning a significant matter that may lead to a change in control [6] - The stock will be suspended from trading starting January 9, 2026, for up to two trading days [6] Group 7 - Hu Silicon Industry reported that the National Integrated Circuit Industry Investment Fund reduced its stake by 0.2%, from 17.16% to 16.96% [9] Group 8 - Guangdong Yuedian A announced that the 5th unit of the Huizhou Power Plant expansion project has been put into operation, with a total investment of 8.05 billion yuan [10] - The project is expected to generate an annual power output of 8.84 billion kWh, which is significant for expanding the company's power generation capacity [10] Group 9 - Tianneng Co., Ltd. plans to use up to 12 billion yuan of idle funds for entrusted wealth management, focusing on low to medium-risk financial products [11] Group 10 - Quanxin Co., Ltd. plans to issue convertible bonds to raise up to 312 million yuan for commercial aviation transmission and communication integration projects [12] Group 11 - Meike Home announced a significant loss and decided to suspend operations at its Tianjin manufacturing facilities due to low utilization rates [13] - The company aims to optimize idle capacity and reduce losses while ensuring employee rights during the transition [13] Group 12 - Aimeike announced that its exclusive distributor for botulinum toxin products received a drug registration certificate, marking a key milestone in its strategic layout [14] Group 13 - Pairui Co., Ltd. signed a framework agreement for bulk procurement of IGBT chips, with projected supply amounts totaling approximately 1.3 to 1.4 billion yuan for 2028-2030 [15]

智通财经APP讯，爱美客(300896.SZ)公告，公司在中国独家经销韩国Huons BP生产的注射用A型肉毒毒 素产品获得国家药品监督管理局核准签发的《药品注册证书》。 ...

人民财讯1月8日电，爱美客（300896）1月8日公告，1月8日，公司在中国（包括澳门和香港）独家经销 韩国 Huons BP生产的注射用A型肉毒毒素产品获得国家药监局核准签发的《药品注册证书》。 ...

人民财讯1月8日电，爱美客(300896)1月8日公告，1月8日，公司在中国（包括澳门和香港）独家经销韩 国 Huons BP生产的注射用A型肉毒毒素产品获得国家药监局核准签发的《药品注册证书》。 转自：证券时报 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 爱美客(300896.SZ)公告称，公司在中国（包括澳门和香港）独家经销的韩国Huons BioPharma Co., Ltd. 生产的注射用A型肉毒毒素产品于2026年1月8日获得国家药品监督管理局核准签发的《药品注册证 书》。该产品通过与现有产品的组合，能为客户提供更全面的综合解决方案，有利于增强公司的核心竞 争力。但该产品进口与销售受境内外法规政策、市场环境、汇率波动等因素的影响，存在不确定性。同 时，经销协议履行中可能存在因不可抗力或其他原因而延期、变更、中止或终止的风险。 ...